BCA
VIVO

Berman Capital Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Berman Capital Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-235
Closed -$4K – 1618
2019
Q1 		$4K Hold
235
– – ﹤0.01% 955
2018
Q4 		$4K Buy
+235
New +$4.01K ﹤0.01% 769

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berman Capital Advisors's VIVO Position: Q2 2019 in Review

Berman Capital Advisors sold out of Meridian Bioscience Inc (VIVO) in Q2 2019, closing a stake of 235 shares — an estimated $4K sold.

Berman Capital Advisors first reported a position in VIVO in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 173 funds tracked by Wall St. Rank hold VIVO as of Q2 2019.

  • Berman Capital Advisors reported no remaining Meridian Bioscience Inc position as of Q2 2019 after selling out during the quarter.
  • Berman Capital Advisors sold 235 Meridian Bioscience Inc shares in Q2 2019, an estimated $4K.
  • Berman Capital Advisors first reported a position in Meridian Bioscience Inc in Q4 2018 and held it in 2 quarters.
  • Berman Capital Advisors's Meridian Bioscience Inc position peaked at $4K in Q1 2019.
  • 173 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2019.

Based on Berman Capital Advisors's 13F filing for Q2 2019, filed 30 Jul 2019.